Clinical Challenges: Allo-Transplant in Hodgkin's Lymphoma
email article About 90-95% of patients with Hodgkin's lymphoma (HL) obtain durable remissions with currently available treatment, including traditional chemotherapeutic strategies and, more recently, with novel agents such as the antibody-drug conjugate brentuximab vedotin (Adcetris) and the immune checkpoint inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda). The availability of multiple highly effective therapies raises legitimate questions about the current and future role of autologous stem-cell transplant (ASCT), long a mainstay of treatment in relapsed/refractory HL, Lesli...
Source: medpagetoday.com